Cancer’s Vulnerability is Our Strength

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

Learn More

Scientific Approach

At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.

Pipeline

Novel, drug candidates targeting key cancer vulnerabilities

LEARN MORE

Patients

Enrollment is open in our Phase 1/2 trial for solid tumors and hematologic malignancies

LEARN MORE

Careers

At Cyteir, patients come first, science is key and collaboration is valued. Come join us!

LEARN MORE

Cyteir’s Culture

With a pioneering spirit, putting patients first, we advance science passionately and collaboratively, in a fun learning environment. We value open, honest and transparent communication. We work diligently with respect for each other with a sense of urgency, integrity, accountability and purpose.​

Learn More

“Cyteir is a clinical stage oncology company that’s focused entirely on the discovery and development of next-generation synthetically lethal therapies for the treatment of cancer. We’re using our expertise in translating new biological discoveries to advance a pipeline of novel drugs that create synthetic lethality and target these cancer vulnerabilities.”

Markus Renschler, MD
President and Chief Executive Officer